Shares of Guardant Health, Inc. (NASDAQ:GH – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $39.67.
Several equities research analysts have recently issued reports on GH shares. Bank of America raised their price objective on Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 18th. UBS Group increased their price target on Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 21st. Craig Hallum increased their price target on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Guggenheim upgraded Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Friday, June 28th. Finally, JPMorgan Chase & Co. increased their price target on Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th.
Get Our Latest Stock Report on Guardant Health
Institutional Inflows and Outflows
Guardant Health Price Performance
NASDAQ:GH opened at $22.16 on Wednesday. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -5.65 and a beta of 1.11. Guardant Health has a 1 year low of $15.81 and a 1 year high of $37.04. The business has a 50 day simple moving average of $26.92 and a 200-day simple moving average of $25.38. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.40 and a quick ratio of 6.07.
Guardant Health (NASDAQ:GH – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The company had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. Guardant Health’s revenue for the quarter was up 29.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.67) earnings per share. Equities analysts forecast that Guardant Health will post -3.31 EPS for the current year.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading
- Five stocks we like better than Guardant Health
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- How to invest in marijuana stocks in 7 stepsĀ
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.